二妙丸不同配伍比例对大鼠高尿酸血症的影响

Effects of Ermiao Pill for different compatibility proportion on the treatment of hyperuricemic rats

关键词:  二妙丸  不同配比  高尿酸血症

Key words:  Ermiao Pill  compatibility  high uric acid hematic disease

摘要:

[目的] 研究二妙丸不同配伍比例对高尿酸血症大鼠尿酸的影响。[方法] 采用酵母膏15 g/kg+腺嘌呤100 mg/kg+氧嗪酸钾300 mg/kg联合用药制备大鼠高尿酸血症模型。将100只雄性SD大鼠随机分为10组，分别是空白对照组、模型组、苍术：黄柏1：1组（简称苍黄1：1组）、苍术：黄柏1：2组（苍黄1：2组）、苍术：黄柏2：1组（苍黄2：1组）、苍术：黄柏1：3组（苍黄1：3组）、苍术：黄柏3：1组（苍黄3：1组）、苍术：黄柏1：0组（苍黄1：0组）、苍术：黄柏0：1组（苍黄0：1组）、阳性药组（别嘌呤醇15 mg/kg）。除空白对照组给予同体积生理盐水外，其他各组大鼠分别连续7 d给予酵母膏15 g/kg+腺嘌呤100 mg/kg灌胃造模，同时各比例组给予生药4.8 g/kg二妙丸，于最后1 d灌胃1次氧嗪酸钾300 mg/kg 1次，1 h后取材，通过检测大鼠血清尿酸（BUA）、黄嘌呤氧化酶（XOD）、肌酐（SCr）、尿素氮（BUN）、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、总胆固醇（T-CHO）、甘油三酯（TG）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）水平，观察大鼠尿液中尿肌酐（UCr）、尿尿素氮（UUN）、24 h尿量（24 h UV）、24 h尿酸排泄量（24 h UUA）水平，及肝肾质量和肝肾脏器系数，研究二妙丸不同配伍比例对大鼠高尿酸血症的影响。[结果] 与模型组比较，二妙丸各比例治疗组及阳性药组大鼠的BUA、XOD（除苍黄3：1、1：0、0：1组）、SCr、24 h UV（除苍黄0：1组、阳性药组）、24 h UUA、T-CHO、TG（除阳性药组）、HDL-C、LDL-C、肝脏质量及肝脏脏器系数（除阳性药组）、肾脏质量和肾脏脏器系数水平显著降低（P<0.05或P<0.01）。与模型组比较，各治疗组均能显著提高大鼠UCr（除苍黄1：0组）、UUN（除苍黄3：1组）水平（P<0.05或P<0.01），而大鼠ALT（除苍黄1：2组）、AST水平有升高趋势但并无显著性差异（P>0.05）。[结论] 综合以上指标，初步表明二妙丸不同配伍比例具有显著降低高尿酸血症大鼠BUA、XOD水平并促进肾脏尿酸排泄、改善肾功能、调节血脂水平的作用，其中苍黄1：2组效果较为显著。

Abstract:

[Objective] To investigate the effects of Ermiao Pill for different compatibility proportion on the treatment of hyperuricemic SD rats.[Methods] Using yeast extract 15 g/kg+adenine oxazine 100 mg/kg+oxygen acid potassium 300 mg/kg combination in the preparation of high uric acid hematic disease model in rats. 100 male rats were randomly divided into 10 groups, respectively is the blank group, model group, rhizoma atractylodis, cortex phellodendri, 1:1 group, rhizoma atractylodis, cortex phellodendri, 1:2 group, rhizoma atractylodis, cortex phellodendri, 2:1, rhizoma atractylodis, cortex phellodendri, 1:3 group, rhizoma atractylodis, cortex phellodendri group 3:1 group, the rhizoma atractylodis, cortex phellodendri, 1:0, rhizoma atractylodis, cortex phellodendri 0:1 group, positive drug group (allopurinol 15 mg/kg). Groups respectively ig give rats 1 week in a row, after the last delivery, by detecting the serum concentration of UA, Cre, BUN, serum ALT, AST, T-CHO, TG, HDL, LDL-C-C level, observed in the urine of rats 24 h uua, Cre, BUN, 24 h uv, and quality of liver, kidney and coefficient, evaluation of Ermiao Pill for different compatibility of uric acid.[Results] Compared with model group, Ermiao Pill rate in treatment group and positive medicine group of rats serum uric acid levels were significantly lower (P<0.01), of which highlights 1:2 group effect is significant. Compared with model control group, serum creatinine, 24 h urine (except highlights 1:0 group, positive drug group), 24 h level of uric acid excretion, kidney, kidney coefficient of quality level increased significantly(P<0.05 or P<0.01), urinary creatinine and urea nitrogen levels (except group highlights 3:1), 24 h urine uric acid decreased significantly(P<0.05 or P<0.01). Compared with model group, the proportion of groups and positive medicine group can improve the level of ALT and AST of rats but no significant difference(P>0.05), the quality of the liver and liver coefficient in addition to the positive medicine group were significantly lower than model group(P<0.05 or P<0.01). Compared with model group, in addition to the positive medicine group failed to significantly reduce the TG level (P>0.05), and the rest of the group can significantly reduce the T-CHO, TG, HDL, LDL-C level(P<0.05 or P<0.01).[Conclusion] Ermiao Pill for different compatibility proportion have significantly reduced the high uric acid hematic disease uric acid levels in rats and improve renal uric acid excretion, renal function, the function of regulating blood lipid level. Especially highlights 1:2 group effect is significant, and is superior to other groups.